Regorafenib in the treatment of malignant tumor
10.3760/cma.j.issn.1673-422X.2013.03.009
- VernacularTitle:Regorafenib治疗恶性肿瘤的研究进展
- Author:
Mengxi GE
;
Xiaohua LIANG
- Publication Type:Journal Article
- Keywords:
Receptor protein-tyrosine kinases;
Enzyme inhibitors;
Neoplasms
- From:
Journal of International Oncology
2013;(3):191-192,231
- CountryChina
- Language:Chinese
-
Abstract:
Regorafenib,an oral multi-kinase inhibitor,can inhabit a class of receptor tyrosine kinase,such as angiogenic,stromal,oncogenic and so on.Studies in vitro and clinical trials indicate that Regorafenib has significant antitumor activity.The results of clinical trials are encouraging for the treatment of Refractory solid tumors,especially for colorectal carcinoma.
